Champlain Investment Partners LLC Has $65.61 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Champlain Investment Partners LLC cut its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 4.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,473,639 shares of the company's stock after selling 73,365 shares during the period. Champlain Investment Partners LLC owned about 3.18% of Omnicell worth $65,606,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its position in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares in the last quarter. Van ECK Associates Corp raised its holdings in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC acquired a new position in Omnicell during the fourth quarter valued at approximately $53,000. First Horizon Advisors Inc. grew its stake in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares in the last quarter. Finally, Huntington National Bank increased its position in shares of Omnicell by 236.4% during the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after purchasing an additional 955 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on OMCL shares. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Benchmark reissued a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. cut their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, April 15th. Finally, Wells Fargo & Company reduced their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $50.67.

Omnicell Price Performance

Omnicell stock traded up $0.18 during mid-day trading on Tuesday, reaching $29.83. 150,099 shares of the company were exchanged, compared to its average volume of 532,679. The firm has a market cap of $1.40 billion, a PE ratio of 110.62, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a fifty day simple moving average of $35.06 and a 200-day simple moving average of $41.18.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.